Janux Therapeutics, Inc. — Q2 2023 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2023. Janux is a clinical-stage biopharmaceutical company developing tumor-activated cancer immunotherapies through its TRACTr and TRACIr platforms. It has no product sales; reported revenue is from its Merck collaboration.
Financial performance and liquidity
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Collaboration revenue | $1.1 million | $2.4 million | $3.1 million | $4.0 million |
| Research and development expense | $14.9 million | $14.1 million | $30.8 million | $24.3 million |
| General and administrative expense | $6.9 million | $5.5 million | $13.3 million | $10.5 million |
| Net loss | $17.5 million | $16.9 million | $35.0 million | $30.3 million |
| Net loss per share, basic and diluted | $0.42 | $0.41 | $0.84 | $0.73 |
- Six-month operating cash outflow was $29.0 million, versus $17.6 million in 2022. Investing activities provided $9.1 million, mainly from net investment maturities; financing provided $2.1 million.
- At June 30, cash and cash equivalents were $33.7 million and short-term investments were $269.6 million; restricted cash was $0.8 million. Cash, cash equivalents and short-term investments totaled approximately $303.3 million, excluding restricted cash.
- Current assets were $309.3 million and current liabilities $17.9 million. The company reported no borrowings; operating lease liabilities totaled $25.2 million, including $1.4 million current. Accumulated deficit was $145.4 million.
- Margins are not meaningful for this pre-commercial company; it has not generated product revenue.
Changes versus prior comparable periods
- For the first half, revenue declined $0.8 million as Merck research-service hours decreased. Operating expenses rose $9.4 million, including R&D up $6.5 million and G&A up $2.9 million; the net loss widened $4.7 million.
- Higher interest rates drove interest income to $6.1 million for the first half, versus $0.5 million in 2022, partially offsetting higher operating losses.
- R&D spending shifted among programs: first-half JANX007 direct costs rose $1.4 million and JANX008 costs declined $2.2 million; preclinical and unallocated direct costs and indirect costs increased.
- Available-for-sale investments had $1.1 million of gross unrealized losses at June 30, which management attributed primarily to interest-rate and market conditions, not credit factors. No credit-loss allowance was recorded.
Outlook, commentary and risks
- Management said existing cash and cash equivalents and short-term investments should fund anticipated needs for at least 12 months following the filing. The company expects substantial losses and increased R&D and G&A expenses and says additional financing will be needed to develop candidates through approval and commercialization.
- In July 2023, after quarter-end, Janux completed an underwritten offering of common stock and pre-funded warrants for $59.0 million gross proceeds and estimated $56.5 million net proceeds. Management said the additional capital positions it to advance another program into clinical trials; it was assessing preclinical pipeline priorities.
- JANX007 was in a Phase 1 trial for metastatic castration-resistant prostate cancer. Janux reported July interim data with PSA reductions and described a potentially differentiated profile in CRS, healthy-tissue toxicity and pharmacokinetics; these were preliminary company-reported findings, not confirmatory outcomes.
- JANX008 was in Phase 1 development for several solid tumors; its first patient was dosed in April 2023. The company expected to select a TROP2-TRACTr development candidate and be ready to submit an IND for JANX009 in 2023.
- Merck has selected two collaboration targets. Remaining performance obligations primarily concern research and joint-committee work for the second target, with an estimated 1.2 years of research services remaining at June 30. Merck may terminate the agreement unilaterally; milestones and royalties are contingent.
- Key risks include early-stage clinical uncertainty, safety risks including cytokine release syndrome and healthy-tissue toxicity, reliance on third-party clinical and manufacturing providers, need for future capital and potential dilution, dependence on Merck collaboration revenue, and macroeconomic, banking, inflation and interest-rate conditions. The company reported no material legal proceedings and said disclosure controls were effective.
Important facts for investors to verify
- Review the full JANX007 interim clinical dataset, including patient numbers, dose levels, duration of follow-up, safety events and durability of PSA responses.
- Track JANX008 trial progress and the timing and evidence supporting the expected TROP2 candidate selection and JANX009 IND submission.
- Reassess cash runway using actual clinical-trial spending, the July offering’s final net proceeds and any future financing or ATM issuance.
- Monitor Merck research activity, remaining performance obligations, target progress and any milestone, termination or royalty developments.
- Assess investment portfolio liquidity and interest-rate exposure, as well as the dilution impact of outstanding options, reserved shares and future equity issuance.